SP Asset Management LLC Lowers Position in Humana Inc. (NYSE:HUM)

SP Asset Management LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 3.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,127 shares of the insurance provider’s stock after selling 46 shares during the quarter. SP Asset Management LLC’s holdings in Humana were worth $286,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp raised its stake in Humana by 1.0% during the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after acquiring an additional 53,272 shares during the period. FMR LLC lifted its stake in Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Pzena Investment Management LLC lifted its stake in Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its stake in Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock worth $371,705,000 after purchasing an additional 71,910 shares in the last quarter. Finally, Sanders Capital LLC lifted its stake in Humana by 1.0% in the 3rd quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider’s stock worth $370,060,000 after purchasing an additional 11,923 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Down 0.3 %

Shares of HUM opened at $262.10 on Thursday. The firm has a fifty day moving average price of $271.53 and a 200-day moving average price of $284.92. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $31.62 billion, a P/E ratio of 26.34, a P/E/G ratio of 2.05 and a beta of 0.57. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Equities research analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.35%. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.32% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and lifted their price objective for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Morgan Stanley reduced their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Finally, Barclays lifted their price objective on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Twenty equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.